Substituted 3,6-diazabicyclo[3.2.0]heptanes

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

ring A of the bicyclic ring system is optionally substituted at a carbon atom by one or more C 1-4 alkyl;

ring B of the bicyclic ring system is optionally substituted at a carbon atom by one or more C 1-4 alkyl;

G is phenyl or a 5-6 membered heteroaryl, each of which is optionally substituted by one, two, three, or four substituents selected from the group consisting of halogen, SF 5 , CN, OH, NH 2 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl, C(═O)NH 2 and C(═O)OR 3 ;

G 1 is phenyl, a 5-6-membered heteroaryl, or an 8-11 membered heteroaryl, each of which is optionally substituted by one, two, three, or four substituents selected from the group consisting of halogen, SF 5 , CN, OH, NH 2 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C(═O)NH 2 , and C(═O)(O) z R 3 ;

R is H, C 1-4 alkyl, or C 1-4 alkoxy;

each R 1 is independently H, F, OH, C 1-4 alkyl, or C 1-4 alkoxy;

each R 2 is independently H, F, OH, C 1-4 alkyl, or C 1-4 alkoxy;

R 3 is H or C 1-4 alkyl;

R 4 is H, C 1-4 alkyl, C(═O)C 1-4 alkyl, C(═O)C 1-4 alkoxyC 1-4 alkyl, or C(═O)cyclopropyl;

R 5 is H or C 1-4 alkyl;

R 6 is H or C 1-4 alkyl;

W is —CHR 2 —, —NR 3 —, —O—, —S— or S(═O) 2 —;

Y is phenyl, which is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, SF 5 , CN, OH, C(═O) NHR 4 , NR 5 R 6 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl, and C(═O)(O) z R 3 ; or

Y is an 8-11 membered heteroaryl, which is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, SF 5 , CN, OH, C(═O) NHR 4 , NR 5 R 6 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl, and C(═O)(O) z R 3 ; or

Y is a 5-6 membered heteroaryl, which is optionally substituted by one, two, or three substituents selected from the group consisting of oxo, halogen, SF 5 , CN, OH, NR 5 R 6 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl, C(═O)(O) z R 3 , C(═O)NH 2 , and (CH 2 ) z C(═O)N(R 4 R 5 ), provided that oxo can only be a substituent for a carbon atom; or

Y is a monocyclic saturated 3-7 membered carbocyclyl, which is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, SF 5 , CN, OH, NR 5 R 6 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl, C(═O)NH 2 , and C(═O)(O) z R 3 , and wherein one or more carbon atoms is optionally replaced by —N(R 4 ) z —, —O— or —S—; or

Y is a bicyclic 8-11 membered carbocyclyl, each of which is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, SF 5 , CN, OH, NR 5 R 6 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl, C(═O)NH 2 , and C(═O)(O) z R 3 , and wherein one or more carbon atoms is optionally replaced by —N(R4)z-, —O— or —S—;

m is 1 or 2;

n is 0 or 1;

p is 1 or 2; and

z is 0 or 1.

2. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein:

Y is phenyl, which is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, SF 5 , CN, OH, C(═O) NHR 4 , NR 5 R 6 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl, and C(═O)(O) z R 3 ; or

Y is an 8-11 membered heteroaryl, which is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, SF 5 , CN, OH, C(═O) NHR 4 , NR 5 R 6 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl, and C(═O)(O) z R 3 ; or

Y is a 5-6 membered heteroaryl, which is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, SF 5 , CN, OH, C(═O) NHR 4 , NR 5 R 6 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl, and C(═O)(O) z R 3 ; or

Y is a monocyclic saturated 3-7 membered carbocyclyl, which is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, SF 5 , CN, OH, C(═O) NHR 4 , NR 5 R 6 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl, and C(═O)(O) z R 3 ; or

Y is a bicyclic 8-11 membered carbocyclyl, each of which is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, SF 5 , CN, OH, C(═O) NHR 4 , NR 5 R 6 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl, and C(═O)(O) z R 3 .

3. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein:

G is phenyl or a 5-6 membered heteroaryl, each of which is optionally substituted by one, two, three, or four substituents selected from the group consisting of halogen, SF 5 , CN, OH, NH 2 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl, C(═O)NH 2 and C(═O)OR 3 ;

G 1 is phenyl, a 5-6-membered heteroaryl, or an 8-11 membered heteroaryl, each of which is optionally substituted by one, two, three, or four substituents selected from the group consisting of halogen, SF 5 , CN, OH, NH 2 , NHC 1-4 alkyl, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C(═O)NH 2 , and C(═O)(O) z R 3 ;

R is H, C 1-4 alkyl, or C 1-4 alkoxy;

each R 1 is independently H, F, OH, C 1-4 alkyl, or C 1-4 alkoxy;

each R 2 is independently H, F, OH, C 1-4 alkyl, or C 1-4 alkoxy;

R 3 is H or C 1-4 alkyl;

W is —CHR 2 —, —NR 3 —, —O—, —S— or —S(═O) 2 —;

Y is a 5-6 membered heteroaryl, which is optionally substituted by one or two substituents selected from the group consisting of halogen, SF 5 , CN, OH, NH 2 , C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl, C(═O)(O) z R 3 , and C(═O)NH 2 ; or

Y is a monocyclic saturated 3-7 membered carbocyclyl, which is optionally substituted by one or two substituents selected from the group consisting of halogen, SF 5 , CN, OH, NH 2 , C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl, C(═O)NH 2 , and C(═O)(O) z R 3 ; or

m is 1 or 2;

n is 0 or 1; and

p is 1 or 2.

4. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein:

5. The compound of claim 4 , or the pharmaceutically acceptable salt thereof, wherein:

6. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein:

G is phenyl or a 6-member heteroaryl, each of which is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1-4 alkylamino, C 1-4 alkyl, haloC 1-4 alkyl, and C 1-4 alkoxy;

G 1 is 5-6 membered heteroaryl optionally substituted by one, two, or three substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1-4 alkylamino, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl, and C(═O)NH 2 ;

R is H;

each R 1 is independently H;

each R 2 is independently H;

W is —CH 2 —, —O— or —S—;

Y is a 5-6 membered heteroaryl, which is optionally substituted by one or two substituents selected from the group consisting of halogen, CN, OH, NH 2 , C 1-4 alkylamino, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl, and C(═O)NH 2 ;

m is 1;

n is 1; and

p is 1.

7. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (I-1) or a pharmaceutically acceptable salt thereof:

8. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (I-2) or a pharmaceutically acceptable salt thereof:

9. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 , wherein the compound is:

13. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. A method for modulating a dopamine D 3 receptor in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the compound of claim 1 .

15. The method of claim 14 , wherein modulating the dopamine D 3 receptor is treating a medical condition that is impacted by the dopamine D 3 receptor.

16. The method of claim 15 , wherein the medical condition is a psychiatric condition.

17. The method of claim 15 , wherein the psychiatric condition is schizophrenia.

18. The method of claim 15 , wherein the medical condition is opioid use disorder or alcohol dependency.

19. The method of claim 15 , wherein the medical condition is gambling.